Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

Robert Perrillo, Carlo Tamburro, Fredric Regenstein, Luis Balart, Henry Bodenheimer, Marcelo Silva, Eugene R Schiff, Carol Bodicky, Barbara Miller, Cheryl Denham, Carmel Brodeur, Kathy Roach, Janice Albrecht

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Background & Aims: Interferon therapy has been associated with a number of severe side effects when administered to patients with decompensated cirrhosis caused by chronic hepatitis B. The safety and potential efficacy of a low-dose, titratable regimen of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B virus infection were studied. Methods: Twenty-six patients were treated at five medical centers. Five patients had Child's class A status, 15 had Child's B status, and 6 had Child's C status. Treatment was continued for 24 weeks whenever possible. Dose adjustments were made according to predefined safety criteria. Results: All patients with Child's A status responded with a sustained loss of serum hepatitis B virus DNA, reduction in aminotransferase activity, and clinical stabilization. Only 5 patients with Child's B (33%) and no patients with Child's C status reached similar end points. The probability of survival was greater in responders than in nonresponders (P = 0.017). Three patients each developed serious infections or greater than twofold increases in serum aminotransferase levels during therapy. Conclusions: Low-dose, titratable interferon therapy is safer than previously reported regimens. Nonetheless, serious infections were observed relatively frequently, and this therapy should be reserved for individuals with mild to moderate hepatic decompensation, preferably patients with Child's A status.

Original languageEnglish
Pages (from-to)908-916
Number of pages9
JournalGastroenterology
Volume109
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Hepatitis B virus
Interferon-alpha
Liver Diseases
Infection
interferon alfa-2b
Chronic Hepatitis B
Transaminases
Interferons
Therapeutics
Safety
Virus Diseases
Serum
Fibrosis
Survival
Liver
DNA

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Perrillo, R., Tamburro, C., Regenstein, F., Balart, L., Bodenheimer, H., Silva, M., ... Albrecht, J. (1995). Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology, 109(3), 908-916. https://doi.org/10.1016/0016-5085(95)90401-8

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. / Perrillo, Robert; Tamburro, Carlo; Regenstein, Fredric; Balart, Luis; Bodenheimer, Henry; Silva, Marcelo; Schiff, Eugene R; Bodicky, Carol; Miller, Barbara; Denham, Cheryl; Brodeur, Carmel; Roach, Kathy; Albrecht, Janice.

In: Gastroenterology, Vol. 109, No. 3, 01.01.1995, p. 908-916.

Research output: Contribution to journalArticle

Perrillo, R, Tamburro, C, Regenstein, F, Balart, L, Bodenheimer, H, Silva, M, Schiff, ER, Bodicky, C, Miller, B, Denham, C, Brodeur, C, Roach, K & Albrecht, J 1995, 'Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus', Gastroenterology, vol. 109, no. 3, pp. 908-916. https://doi.org/10.1016/0016-5085(95)90401-8
Perrillo, Robert ; Tamburro, Carlo ; Regenstein, Fredric ; Balart, Luis ; Bodenheimer, Henry ; Silva, Marcelo ; Schiff, Eugene R ; Bodicky, Carol ; Miller, Barbara ; Denham, Cheryl ; Brodeur, Carmel ; Roach, Kathy ; Albrecht, Janice. / Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. In: Gastroenterology. 1995 ; Vol. 109, No. 3. pp. 908-916.
@article{cac68f99008346aa99640f3b7a348b50,
title = "Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus",
abstract = "Background & Aims: Interferon therapy has been associated with a number of severe side effects when administered to patients with decompensated cirrhosis caused by chronic hepatitis B. The safety and potential efficacy of a low-dose, titratable regimen of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B virus infection were studied. Methods: Twenty-six patients were treated at five medical centers. Five patients had Child's class A status, 15 had Child's B status, and 6 had Child's C status. Treatment was continued for 24 weeks whenever possible. Dose adjustments were made according to predefined safety criteria. Results: All patients with Child's A status responded with a sustained loss of serum hepatitis B virus DNA, reduction in aminotransferase activity, and clinical stabilization. Only 5 patients with Child's B (33{\%}) and no patients with Child's C status reached similar end points. The probability of survival was greater in responders than in nonresponders (P = 0.017). Three patients each developed serious infections or greater than twofold increases in serum aminotransferase levels during therapy. Conclusions: Low-dose, titratable interferon therapy is safer than previously reported regimens. Nonetheless, serious infections were observed relatively frequently, and this therapy should be reserved for individuals with mild to moderate hepatic decompensation, preferably patients with Child's A status.",
author = "Robert Perrillo and Carlo Tamburro and Fredric Regenstein and Luis Balart and Henry Bodenheimer and Marcelo Silva and Schiff, {Eugene R} and Carol Bodicky and Barbara Miller and Cheryl Denham and Carmel Brodeur and Kathy Roach and Janice Albrecht",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0016-5085(95)90401-8",
language = "English",
volume = "109",
pages = "908--916",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

AU - Perrillo, Robert

AU - Tamburro, Carlo

AU - Regenstein, Fredric

AU - Balart, Luis

AU - Bodenheimer, Henry

AU - Silva, Marcelo

AU - Schiff, Eugene R

AU - Bodicky, Carol

AU - Miller, Barbara

AU - Denham, Cheryl

AU - Brodeur, Carmel

AU - Roach, Kathy

AU - Albrecht, Janice

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background & Aims: Interferon therapy has been associated with a number of severe side effects when administered to patients with decompensated cirrhosis caused by chronic hepatitis B. The safety and potential efficacy of a low-dose, titratable regimen of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B virus infection were studied. Methods: Twenty-six patients were treated at five medical centers. Five patients had Child's class A status, 15 had Child's B status, and 6 had Child's C status. Treatment was continued for 24 weeks whenever possible. Dose adjustments were made according to predefined safety criteria. Results: All patients with Child's A status responded with a sustained loss of serum hepatitis B virus DNA, reduction in aminotransferase activity, and clinical stabilization. Only 5 patients with Child's B (33%) and no patients with Child's C status reached similar end points. The probability of survival was greater in responders than in nonresponders (P = 0.017). Three patients each developed serious infections or greater than twofold increases in serum aminotransferase levels during therapy. Conclusions: Low-dose, titratable interferon therapy is safer than previously reported regimens. Nonetheless, serious infections were observed relatively frequently, and this therapy should be reserved for individuals with mild to moderate hepatic decompensation, preferably patients with Child's A status.

AB - Background & Aims: Interferon therapy has been associated with a number of severe side effects when administered to patients with decompensated cirrhosis caused by chronic hepatitis B. The safety and potential efficacy of a low-dose, titratable regimen of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B virus infection were studied. Methods: Twenty-six patients were treated at five medical centers. Five patients had Child's class A status, 15 had Child's B status, and 6 had Child's C status. Treatment was continued for 24 weeks whenever possible. Dose adjustments were made according to predefined safety criteria. Results: All patients with Child's A status responded with a sustained loss of serum hepatitis B virus DNA, reduction in aminotransferase activity, and clinical stabilization. Only 5 patients with Child's B (33%) and no patients with Child's C status reached similar end points. The probability of survival was greater in responders than in nonresponders (P = 0.017). Three patients each developed serious infections or greater than twofold increases in serum aminotransferase levels during therapy. Conclusions: Low-dose, titratable interferon therapy is safer than previously reported regimens. Nonetheless, serious infections were observed relatively frequently, and this therapy should be reserved for individuals with mild to moderate hepatic decompensation, preferably patients with Child's A status.

UR - http://www.scopus.com/inward/record.url?scp=0029087266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029087266&partnerID=8YFLogxK

U2 - 10.1016/0016-5085(95)90401-8

DO - 10.1016/0016-5085(95)90401-8

M3 - Article

VL - 109

SP - 908

EP - 916

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -